EyeGene, Inc.

As of March 31, 2026, EyeGene, Inc. carries a market capitalization of 61.59B, placing it among publicly traded companies globally. Its enterprise value stands at 17.46B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, EyeGene, Inc. has 43.22M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 11.98, and the price-to-book ratio stands at 1.14.

These figures are as of March 31, 2026. The EV/Sales ratio of 4.34 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 17.46B versus a market cap of 61.59B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, EyeGene, Inc. maintains a current ratio of 4.37, meaning it holds 4.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.03, indicating moderate leverage, while an interest coverage ratio of -34.49 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, EyeGene, Inc. posted a negative return on equity (ROE) of -31.99, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -25.39, reflecting losses generated across the asset base. The company generates approximately 81.23M in revenue per employee across its workforce of 49.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.32 indicates how many times EyeGene, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 23, 2026, EyeGene, Inc.'s stock has declined approximately 7.20% over the past 52 weeks. The 50-day moving average sits at 1,935.86, while the 200-day moving average is 1,605.71.

Over the twelve months ended March 31, 2026, EyeGene, Inc. generated 4.02B in revenue and converted that into -16.22B in net income, yielding earnings per share of -581.36. EBITDA reached -9.66B, while operating income came in at -10.89B.

As of March 31, 2026, EyeGene, Inc. holds 41.69B in cash and equivalents against 524.25M in total debt, resulting in a net debt position of -7.16B. Total book value stands at 53.89B, with working capital of 33.94B providing operational flexibility.

EyeGene, Inc. produced -8.47B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -1.22B in capital expenditures, free cash flow totaled -9.69B - equivalent to -286.63 per share.

Over the twelve months ended March 31, 2026, EyeGene, Inc. posted a gross margin of 29.85, reflecting its pricing power and cost economics. The operating margin of -270.73 and net profit margin of -403.35 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -20.11: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -32.40, meaning EyeGene, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

EyeGene, Inc.'s most recent stock split took place on October 24, 2025 with a 95:111 split ratio.

As of March 31, 2026, EyeGene, Inc. has an Altman Z-Score of -1.27, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.